Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 6;10(1):7669.
doi: 10.1038/s41598-020-63466-x.

Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry

Ruth I Tennen  1 , Sarah B Laskey  1 , Bertram L Koelsch  1 , Matthew H McIntyre  1 , Joyce Y Tung  2
Affiliations

Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry

Ruth I Tennen et al. Sci Rep. .

Abstract

Current guidelines recommend BRCA1 and BRCA2 genetic testing for individuals with a personal or family history of certain cancers. Three BRCA1/2 founder variants - 185delAG (c.68_69delAG), 5382insC (c.5266dupC), and 6174delT (c.5946delT) - are common in the Ashkenazi Jewish population. We characterized a cohort of more than 2,800 research participants in the 23andMe database who carry one or more of the three Ashkenazi Jewish founder variants, evaluating two characteristics that are typically used to recommend individuals for BRCA testing: self-reported Jewish ancestry and family history of breast, ovarian, prostate, or pancreatic cancer. Of the 1,967 carriers who provided self-reported ancestry information, 21% did not self-report Jewish ancestry; of these individuals, more than half (62%) do have detectable Ashkenazi Jewish genetic ancestry. In addition, of the 343 carriers who provided both ancestry and family history information, 44% did not have a first-degree family history of a BRCA-related cancer and, in the absence of a personal history of cancer, would therefore be unlikely to qualify for clinical genetic testing. These findings may help inform the discussion around broader access to BRCA genetic testing.

PubMed Disclaimer

Conflict of interest statement

R.I.T., S.B.L., B.L.K, M.H.M. and J.Y.T. are employees of and have stock, stock options, or both, in 23andMe, Inc. The authors declare no other financial or non-financial competing interests.

Figures

Figure 1
Figure 1
Self-reported Jewish ancestry vs. estimated Ashkenazi Jewish genetic ancestry in 1,967 BRCA carriers.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2020, https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.
    1. Committee on Practice Bulletins–Gynecology Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol. 2017;130:e110–e126. doi: 10.1097/AOG.0000000000002296. - DOI - PubMed
    1. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers. JNCI J. Natl. Cancer Inst. 2009;101:80–87. doi: 10.1093/jnci/djn442. - DOI - PMC - PubMed
    1. Owens DK, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322:652–665. doi: 10.1001/jama.2019.10987. - DOI - PubMed
    1. Gabai-Kapara, E. et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc. Natl. Acad. Sci. U.S.A. (2014). - PMC - PubMed

MeSH terms